IDM-1: Phase II data; Phase III

By WIR Staff | May 30, 2000 | 7:00 AM GMT

Among 17 late stage ovarian cancer patients with minimal residual

Read the full 106 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

Article Purchase

This article may not be distributed to non-subscribers

More Info >PURCHASE